Literature DB >> 76796

Is pancreatic polypeptide a marker for Zollinger-Ellison syndrome?

I L Taylor, J H Walsh, J Rotter, E Passaro.   

Abstract

Basal human pancreatic polypeptide (H.P.P.) concentrations have been measured in 41 pateints with Zollinger-Ellison syndrome (Z.E.S.) and in 100 controls. Basal H.P.P. concentrations in controls varied widely from less than 8 pmol/l (assay detection limit) to 313 pmol/l. In controls, but not in the Z.E.S. patients, there was a highly significant positive correlation between basal H.P.P. and age (P less than 0.01). 4 of the Z.E.S. patients (9.8%) and 3 of the controls (3%) had H.P.P. concentrations over 240 pmol/l. These findings indicate that raised basal H.P.P. concentration is an infrequent finding in patients with gastrinomas and therefore it is not a useful tumour marker.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 76796     DOI: 10.1016/s0140-6736(78)90192-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  6 in total

1.  Pancreatic polypeptide.

Authors:  T E Adrian
Journal:  J Clin Pathol Suppl (Assoc Clin Pathol)       Date:  1978

Review 2.  Laboratory tests in the diagnosis of the chronic pancreatic diseases. Part 4. Tests involving the measurement of pancreatic enzymes in body fluid.

Authors:  E J Boyd; H Rinderknecht; K G Wormsley
Journal:  Int J Pancreatol       Date:  1988 Jan-Feb

3.  A meal stimulation test in the diagnosis of pancreatic endocrine tumors in multiple endocrine neoplasia type 1.

Authors:  M Migliori; P Tomassetti; D Campana; S Boschi; R Pezzilli; L Piscitelli; R Corinaldesi; L Gullo
Journal:  Endocrine       Date:  2002-04       Impact factor: 3.633

4.  Abnormal pancreatic polypeptide release by secretin infusion in Zollinger-Ellison syndrome.

Authors:  D Rigaud; J P Accary; M Mignon; S Bonfils
Journal:  Dig Dis Sci       Date:  1984-08       Impact factor: 3.199

5.  The effect of treatment of type 2 (insulin independent) diabetes mellitus on plasma concentrations of pancreatic polypeptide and glucagon.

Authors:  D Berger; J C Floyd; S B Pek
Journal:  Diabetologia       Date:  1981-08       Impact factor: 10.122

6.  Cimetidine-resistant Zollinger-Ellison syndrome: successful management with ranitidine.

Authors:  F M Habal; S J Soldin; G R Greenberg
Journal:  Can Med Assoc J       Date:  1983-08-01       Impact factor: 8.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.